A Multicenter Study of Docetaxel at a Dose of 100 mg/m<sup>2</sup> in Japanese Patients with Advanced or Recurrent Breast Cancer-Reference-Cited by-同舟云学术

A Multicenter Study of Docetaxel at a Dose of 100 mg/m² in Japanese Patients with Advanced or Recurrent Breast Cancer

Published:2021-04-15 Issue:8 Volume:60 Page:1183-1190
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Hirata Taizo¹,Ozaki Shinji²,Tabata Masahiro³,Iwamoto Takayuki⁴,Hinotsu Shiro⁵,Hamada Akinobu⁶,Motoki Takayuki⁷,Nogami Tomohiro⁸,Shien Tadahiko⁴,Taira Naruto⁴,Matsuoka Junji⁴,Doihara Hiroyoshi⁴

Affiliation:

1. Department of Medical Oncology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Japan

2. Department of Breast Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Japan

3. Departments of Allergy and Respiratory Medicine, Okayama University Hospital, Japan

4. Departments of Breast and Endocrine Surgery, Okayama University Hospital, Japan

5. Department of Biostatistics, Sapporo Medical University, Japan

6. Division of Clinical Pharmacology & Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Japan

7. Department of Surgery, Okayama Saiseikai General Hospital, Japan

8. Department of Surgery, Tsuyama Chuo Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/60/8/60_5089-20/_pdf

Reference30 articles.

1. 1. Harvey V, Mouridsen H, Semiglazov V, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24: 4963-4970, 2006.

2. 2. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413-1424, 1999.

3. 3. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23: 5542-5551, 2005.

4. 4. Taguchi T, Mori S, Abe R, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer. Gan To Kagaku Ryoho 21: 2625-2632, 1994 (in Japanese, Abstract in English).

5. 5. Nakamura S, Masuda S, Iwata H, et al. Phase II trial of fluorouracil, epirubicin, cyclophosphamide (FEC) Followed by docetaxel 100 mg/m² in primary operable breast cancer -JBCRG02-. Jpn J Breast Cancer 23: 111-117, 2008 (in Japanese, Abstract in English).

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of maternal taxane chemotherapy exposure on daughters’ ovarian reserve and fertility potential;F&S Science;2023-10

2. Chemotherapeutic Protocols for the Treatment of Breast Cancer;Chemotherapy Protocols and Infusion Sequence;2022

3. Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer;Nanomedicine;2021-02